Latest Partnerships News

Native Mineral Resources Holdings Limited reported a net cash outflow for the December quarter, offset by a $4.1 million entitlement offer and additional funding commitments to sustain exploration activities.

Green Technology Metals (ASX: GT1) secures a Letter of Interest for up to C$100 million financing from Export Development Canada, underpinning its Seymour Lithium Project and advancing drilling and development across its Ontario lithium hubs.

Helios Energy has made significant strides in advancing its flagship Presidio Project in Texas, confirming substantial hydrocarbon resources and strengthening its leadership and financial position.

Lendlease has agreed to sell Capella Capital for $235 million and completed the $516 million sale of its US Military Housing business, reinforcing its strategy to streamline operations and reduce funding needs.

ABx Group reports significant progress in its rare earths and bauxite ventures, including enhanced geological models and pilot plant developments supported by key partnerships and government backing.

Jatcorp Limited faces a sharp revenue drop due to a trademark dispute in China but accelerates growth with new Moroka® products and expanded distribution channels.

Nimy Resources advances its Mons Project with significant high-grade copper and gallium mineralisation confirmed at Masson and Block 3 East prospects, supported by a successful capital raise and a CSIRO research grant.

Lefroy Exploration has reported significant mineral resource upgrades at Burns Central and Mt Martin, alongside a strategic exclusivity agreement with BML Ventures to develop the Lucky Strike Gold Project.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.